# Grifols and Haier Group form strategic alliance for Chinese plasma market

Grifols announced a strategic alliance with Haier Group, selling approximately a 20% equity stake in Shanghai RAAS to Haier for RMB 12.5 billion (approximately USD 1.8 billion) to develop the Chinese plasma market.

- Type: Partnership
- Announced: 2023-12-29
- Where: China
- Value: $1.80B
- Status: announced
- Products: plasma-derived medicines, diagnostic solutions
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Grifols](https://endata.com/companies/23767.md)
- [Haier](https://endata.com/companies/5126.md) (partner)
- [Shanghai RAAS](https://endata.com/companies/74697.md) (target)

## Sources

- [grifols.com](https://www.grifols.com/en/view-news/-/news/grifols-reaches-strategic-alliance-with-haier-group-and-raises-approximately-usd-1-8-billion), 2023-12-29: "The alliance, through Shanghai RAAS (SRAAS), will drive synergies combining Grifols’ expertise and capabilities in pharmaceutical solutions and diagnostic with Haier’s innovative technology to strengthen and enhance China’s healthcare system."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.